Bone Care International Names Brian J. Hayden as Chief Financial Officer.

Business Editors

MIDDLETON, Wis.--(BUSINESS WIRE)--Sept. 2, 2003

Bone Care International, Inc. (Nasdaq:BCII) announced today that Brian J. Hayden has been appointed to the position of Chief Financial Officer, responsible for finance and investor relations, effective October 1, 2003, succeeding Robert A. Beckman who will leave the Company effective September 30, 2003. In this capacity, Mr. Hayden will report directly to Paul L. Berns, President and Chief Executive Officer.

"We are very excited and proud to have Brian Hayden joining our team," said Mr. Berns. "Brian is a seasoned executive with significant broad business experience in the areas of financial management, corporate development and operations, which are directly relevant to the growth opportunities we are exploring."

"Bone Care International is a company that has made significant progress, both in terms of contributions to its patient population and success on the business development front," commented Mr. Hayden. "I am honored to be joining their team and I look forward to working with them towards future growth and profitability."

Mr. Hayden served as Vice President, Chief Financial Officer and Treasurer of Cell Pathways, Inc. from 1997 until its acquisition by OSI Pharmaceuticals, Inc. in June of this year. During his tenure with Cell Pathways, Mr. Hayden guided events that included private financings, a reverse merger taking the company public in 1998, and subsequent PIPE financings. In addition, he managed IT operations and coordinated commercialization activities for an in-licensed product. Prior to his tenure with Cell Pathways, since 1985, Mr. Hayden served as the senior financial executive in five different life science companies, both public and private. Before that, he spent nine years with Hoffmann-La Roche, Inc., in various senior financial management positions. Mr. Hayden began his career on the audit staff of Coopers and Lybrand (now PriceWaterhouseCoopers, LLP). Mr. Hayden, who will be relocating to Wisconsin, received his BBA from Loyola University in Chicago.

Mr. Beckman joined Bone Care International in July 2001 as Vice President Finance and was a member of the Board of Directors from 1989 to July 2002. He will continue to serve as Chief Financial Officer and report to Paul Berns until September 30, 2003. Mr. Berns concluded, "We thank Bob for all of his contributions and dedication to the Company over many years. We understand and respect his decision to move on to other ventures and wish him well."

Bone Care (www.bonecare.com) is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon. Hectorol Injection is approved for the treatment of secondary hyperparathyroidism in patients with end stage renal disease.